title: [Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
abstract: OBJECTIVE
  To evaluate the efficacy of combination chemoimmunotherapy of fludarabine, cyclophosphamide and rituximab (FCR) in chronic lymphocytic leukemia (CLL).
  
  
  METHODS
  Twenty-one patients with CLL were treated with FCR regimen which consisted of fludarabine (25 mg/m(2), days 2 to 4), cyclophosphamide (250 mg/m(2), days 2 to 4) and rituximab (375 mg/m(2), day 1) in a course of 28 days. The minimal residual disease (MRD) was determined by multiparameter flow cytometry. The correlation between the pretreatment characteristics and complete remission (CR) rate was analyzed.
  
  
  RESULTS
  Eleven patients (52.4%) achieved CR, 7 (33.3%) achieved partial remission (PR) with a overall response (OR) rate of 85.7%. With a median follow-up time of 19 (7 - 73) months, the overall survival (OS) was 86.0%, and the progression-free survival (PFS) was 72.0%. Pretreatment parameters independently associated with higher CR rates were Binet stage A + B, IgVH mutated and ZAP-70 less than 20%. MRD was less than 1% in 6 patients. The most common toxicities were myelosuppression and gastrointestinal reaction.
  
  
  CONCLUSIONS
  FCR is an effective regimen for CLL patients.
authors.affiliation: Department of Hematology, Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
authors.forename: Cheng
authors.initials: C
authors.lastname: Fang
authors.forename: Wei
authors.initials: W
authors.lastname: Xu
authors.forename: Min
authors.initials: M
authors.lastname: Xu
authors.forename: Ming
authors.initials: M
authors.lastname: Hong
authors.forename: Dan-xia
authors.initials: DX
authors.lastname: Zhu
authors.forename: Hua-yuan
authors.initials: HY
authors.lastname: Zhu
authors.forename: Yu-jie
authors.initials: YJ
authors.lastname: Wu
authors.forename: Lei
authors.initials: L
authors.lastname: Fan
authors.forename: Chun
authors.initials: C
authors.lastname: Qiao
authors.forename: Yun
authors.initials: Y
authors.lastname: Zhuang
authors.forename: Kou-rong
authors.initials: KR
authors.lastname: Miao
authors.forename: Peng
authors.initials: P
authors.lastname: Liu
authors.forename: Jian-yong
authors.initials: JY
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D016896:Treatment Outcome; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine